Should Opioids Be Used Solely For Severe Pain? FDA Seeks Expert Advice
This article was originally published in The Pink Sheet Daily
The agency is holding a public meeting in February to obtain information on opioid treatment for chronic pain; FDA seeks data to assess whether to restrict use and establish a maximum daily dose.
You may also be interested in...
Physician group appeals for FDA to rescind approval for moderate non-cancer pain and Massachusetts Democrat Rep. William Keating introduces legislation that would bar FDA approval of a non-tamper-resistant opioid drug if the same active moiety already was approved in a tamper-resistant product.
By the third year of continuing medical education efforts, FDA expects 60% of those who wrote a prescription for a long-acting/extended-release opioid in 2011 to receive training.
Pink Sheet reporter and editors discuss the FDA acknowledging reports of malignancies in patients who received CAR-T cell immunotherapies, the agency’s policy for using background music in direct-to-consumer advertising, and the FDA’s new incoming principal deputy commissioner.